Kidney News and Research

RSS

Roche receives FDA approval for CMV viral load test

The U.S. Food and Drug Administration today approved the first DNA test to help health care professionals gauge the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy.

6 Jul 2012

Obesity increases risk of AKI following cardiac surgery

Obesity increases the risk of acute kidney injury (AKI) following cardiac surgery, according to a Vanderbilt study published in the Journal of the American Society of Nephrology.

6 Jul 2012

Hearing loss linked to Alzheimer's, heart disease, chronic kidney diseases and diabetes

Ear plug retailer, All Ear Plugs, urges Brits to take more care in protecting their ears following the release of data from the Better Hearing Institute (BHI) in the US linking hearing loss to chronic diseases.

2 Jul 2012

Surgical injury is increasing dialysis use

Acute dialysis use in patients who experience kidney injury while undergoing major elective surgery has increased substantially over the past 14 years, report researchers in the Canadian Medical Association Journal.

29 Jun 2012

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomised trials published in this week’s Lancet also indicate that the new “Quad” pill is faster acting, doesn’t have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.

29 Jun 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Surgical injury is increasing dialysis use

28 Jun 2012

Harmonizing prescription drug plans can help save millions of dollars

Taxpayers could save millions of dollars if hospitals and provincial governments harmonized their prescription drug plans, new research suggests.

28 Jun 2012

Nanosphere receives FDA marketing approval for Verigene GP Blood Culture Nucleic Acid Test

The U.S. Food and Drug Administration today allowed marketing of the first nucleic acid test that can identify 12 different bacterial types known to cause bloodstream infections.

28 Jun 2012

Scientists reverse diabetes in mice using stem cells

University of British Columbia scientists, in collaboration with an industry partner, have successfully reversed diabetes in mice using stem cells, paving the way for a breakthrough treatment for a disease that affects nearly one in four Canadians.

28 Jun 2012

Registry proves invaluable for fibromuscular dysplasia patients

A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.

27 Jun 2012

Safe vitamin D treatment without raising calcium levels

Patients with a gland disorder that causes excessive calcium in their blood who also have vitamin D deficiency can safely receive vitamin D treatment without it raising their calcium levels, a new study has determined. The results with one-year follow-up will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

Patient registry yields new data that is crucial for early diagnosis and treatment of FMD

27 Jun 2012

Study finds increase in incidence of gout and hyperuricemia in the U.S.

Researchers from Boston University School of Medicine (BUSM) have found that the incidence of gout and hyperuricemia (high uric acid levels) in the U.S. has risen significantly over the last 20 years and is associated with major medical disorders like hypertension and chronic kidney disease.

27 Jun 2012

Vitamin D and calcium supplements could increase risk of kidney stones

Calcium and vitamin D supplements are associated with high calcium levels in the blood and urine, which could increase the risk of kidney stones, a new study finds. The results will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

Chronic kidney disease is major risk factor for future coronary events

People with chronic kidney disease have a 10-year risk for myocardial infarction of around 12%, report researchers who found that this was higher than that for people with diabetes.

26 Jun 2012

New system provides comprehensive remote monitoring solution for the chronically ill

As Europe's population ages, chronic diseases are becoming increasingly widespread. Characterised by gradually deteriorating health and recurring incidents often requiring immediate medical attention, chronic illnesses have a severe impact on patients' autonomy and life quality and are putting increasing strain on over-stretched healthcare systems.

26 Jun 2012

Enrollment commences in Stealth Peptides' Bendavia Phase II clinical study for acute STEMI

Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.

25 Jun 2012

Standard aspirin dose may not protect diabetics against blood clots

Many patients with type 2 diabetes may be aspirin resistant. That means the standard aspirin dose may not protect them against blood clots that cause heart attacks and strokes among diabetics, a new clinical study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012